Back to Search Start Over

Outcomes for recurrent oral cavity squamous cell carcinoma

Authors :
Kevin J. Contrera
Mark E. Zafereo
Dan Yaniv
Diane B. Roberts
Ann M. Gillenwater
Ehab Y. Hanna
Randal S. Weber
Jeffrey N. Myers
Edward I. Chang
Patrick B. Garvey
Matthew M. Hanasono
Peirong Yu
Katherine A. Hutcheson
Clifton D. Fuller
Matthew A. Tyler
David M. Neskey
Source :
Oral Oncology. 134:106127
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

We sought to determine overall survival (OS), prognostic factors, cost, and functional outcomes after surgery for locally recurrent oral cavity squamous cell carcinoma (OCSCC).We retrospectively reviewed 399 cases of locally recurrent OCSCC from 1997 to 2011, of which 259 patients were treated with salvage surgery. Survival and prognostic factors were evaluated using univariable and multivariable Cox regression, the Kaplan-Meier method, and the log-rank test.The 5-year OS for patients undergoing surgical salvage, nonsurgical therapy, or supportive care was 44.2%, 1.5%, and 0%, respectively. For patients who underwent surgical salvage, 133 (51%) patients experienced a second recurrence at a median of 17 months. Factors associated with OS included disease-free interval ≤ 6 months (P =.0001), recurrent stage III-IV disease (P lt;.0001), and prior radiation (P =.0001). Patients with both advanced stage and prior radiation had a 23% 5-year OS, compared with 70% for those with neither risk (P lt;.001). Functionally, 85% of patients had gt; 80% speech intelligibility and 81% were able to eat by mouth following salvage surgery. Of the patients who required tracheostomy, 78% were decannulated. The adjusted median hospital and professional charges for patients were $129,696 (range $9,238-$956,818).Patients with recurrent OCSCC who underwent salvage surgery have favorable functional outcomes with half of alive at 5 years but poorer OS for advanced disease, disease-free interval ≤ 6 months, and prior radiation. Additionally, treatment is associated with high cost, and about half of patients ultimately develop another recurrence.

Details

ISSN :
13688375
Volume :
134
Database :
OpenAIRE
Journal :
Oral Oncology
Accession number :
edsair.doi.dedup.....841b28c1557f539b8662f4a19a6088ce
Full Text :
https://doi.org/10.1016/j.oraloncology.2022.106127